Previous studies suggested the possibility of accelerated lysosomal degradation of brain gangliosides in Alzheimer's disease (AD). As AD pathology affects both neural and nonneural tissues, the aim of this study was to determine possible changes of glycosphingolipid metabolism in available peripheral cells in AD and Down's syndrome (DS). The activities of several lysosomal enzymes involved in catabolism of gangliosides and sulfatides were measured in leukocytes from subjects with dementia of the Alzheimer type, DS, and age-matched controls, by fluorimetry and spectrophotometry using specific substrates. The results showed a statistically significant increase of  -galactosidase activity in both dementia of the Alzheimer type and DS leukocytes when compared with age-matched controls ( p Ͻ .01 and p Ͻ .05, respectively; Student's t test). Not significantly increased activities of  -galactosidase,  -hexosaminidase,  -hexosaminidase A, and slightly decreased activity of arylsulfatase A were observed in control leukocytes with aging. Our results indicate that a metabolic dysfunction and the acceleration of at least some lysosomal catabolic pathways are present in AD and DS nonneural cells. ć LZHEIMER'S disease (AD) is a neurodegenerative disorder of unknown etiology. The hypothesis of disturbed glycosphingolipid (GSL) metabolism in AD is based on several facts. First, previous studies showed changes in content and composition of brain gangliosides in Alzheimer's disease (1), and they suggested the possibility of accelerated lysosomal degradation of GSLs in AD brains (2). Second, numerous studies have shown that pathologic processes and biochemical disturbances in AD affect not only neural but also nonneural tissues (3-10). Third, the majority of biochemical disorders in neural and nonneural tissue result in seriously damaged structure, function, and fluidity of cell membranes (11-15). Finally, gangliosidesGSLs containing sialic acids-are incorporated in all animal cell membranes, with the highest content, variety, and specific regional distribution found in the human brain tissue. As important membrane constituents, GSLs confer to its structural rigidity and are also (themselves or as intermediate metabolites) key players in processes such as cell growth, proliferation, differentiation, cell recognition, and apoptosis (16-20).Down's syndrome (DS) is used as a comparative model for the study of AD: the same clinical symptoms of dementia and the neuropathological hallmarks characteristic of AD are present in older DS individuals (21). Also, similar biochemical disorders have been observed in both AD and DS nonneural tissues (7).The aim of this study was to determine possible changes of GSL metabolism in available peripheral cells derived from subjects with a clinical diagnosis of dementia of the Alzheimer type (DAT) and DS.
M ETHODS
SubjectsBlood samples were collected at the Department for Neurology, University Hospital "Sestre milosrdnice" in Zagreb, from 19 patients (7 men and 12 women, age range 47-86 years; Tab...